According to United Therapeutics, the Office of the Inspector General of the US Department of Health and Human Services has subpoenaed documents related to the marketing of Tyvaso trepostinil inhalation solution for the treatment of pulmonary arterial hypertension. The subpoena covers documents related to two other drugs as well. United Therapeutics says that it plans to cooperate with the investigation.
Sales of Tyvaso totaled $325.6 million in 2012. The product was approved for use with the Optineb-ir nebulizer in 2009; in 2013, the company introduced the TD-100 nebulizer for use with Tyvaso.
Read the United Therapeutics press release.
